Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Current Investments (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cash & Current Investments for 12 consecutive years, with $297.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 8.28% to $297.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $297.0 million, a 8.28% decrease, with the full-year FY2025 number at $297.0 million, down 8.28% from a year prior.
  • Cash & Current Investments was $297.0 million for Q4 2025 at Iovance Biotherapeutics, down from $300.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $626.3 million in Q1 2023 to a low of $164.2 million in Q3 2024.
  • A 3-year average of $320.8 million and a median of $301.0 million in 2025 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: crashed 54.57% in 2024, then surged 83.21% in 2025.
  • Iovance Biotherapeutics' Cash & Current Investments stood at $279.9 million in 2023, then rose by 15.69% to $323.8 million in 2024, then dropped by 8.28% to $297.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cash & Current Investments are $297.0 million (Q4 2025), $300.8 million (Q3 2025), and $301.2 million (Q2 2025).